AOD-9604 Benefits: What the Research Actually Shows

The honest summary of the table: a coherent rodent story, a negative human result for the thing the peptide was designed to do, and no human study at all of the subcutaneous injection that is actually prescribed.

Human growth hormone is a protein of 191 amino acids. AOD-9604 is a synthetic copy of the last fifteen of them, positions 177 to 191, with a tyrosine added at the front, making a 16-amino-acid peptide; it is the same molecule people call "hGH fragment 176-191". AOD stands for Anti-Obesity Drug. It came out of biochemistry work at Monash University in Melbourne and was developed in the late 1990s by an Australian company, Metabolic Pharmaceuticals, as an oral obesity treatment. The idea was to keep the part of growth hormone that seemed to act on fat and leave behind its growth and blood-sugar effects. It is not growth hormone, not a growth hormone secretagogue, and not an appetite drug. The FDA's 2024 review noted that its molecular target has never been identified.

What the research describes. The founding paper, from the Monash group in Hormone Research in 2000, gave obese Zucker rats the fragment orally for 19 days and reported increased lipolytic activity in their fat tissue when tested. A 2001 paper in the International Journal of Obesity gave obese and lean mice growth hormone, the fragment or saline by mini-pump for 14 days, and reported increased whole-body fat oxidation and higher plasma glycerol in the treated obese animals. Glycerol is a marker of fat cells releasing their stored contents.

The proposed route. A 2001 paper in Endocrinology compared the fragment in ordinary obese mice and in mice lacking the beta-3 adrenergic receptor, a receptor on fat cells that drives fat breakdown and heat production. In ordinary obese mice, treatment was associated with more beta-3 receptors in white and brown fat; in the knockout mice, the effects were absent. The reading is that the fragment depends on that receptor system rather than the growth hormone receptor. The FDA's reviewers called this a reasonable inference, not an established mechanism.

Evidence type. Animal.

Strength. Consistent across a small number of rodent studies from closely connected groups. The FDA's 2024 review noted that none of the animal studies established a dose-response relationship and that the statistics were not corrected for multiple comparisons.

What the research describes in animals. Across the Zucker rat and obese mouse work, chronic treatment reduced weight gain compared with controls. The effects were meaningful in those animals.

What happened in people. Between roughly 2001 and 2007 the company ran six randomised, double-blind, placebo-controlled trials in Australia, enrolling close to 900 people, mostly with obesity.

On 21 February 2007 the company announced that the OPTIONS results did not support AOD-9604 as an obesity treatment and ended development for that use. Its own statement said the overall population did not respond consistently.

Evidence type. Human, randomised and placebo-controlled.

Strength. This is the most tested claim on the page, and the test came back negative. The biggest and best-designed human trial, run by the company that invented the peptide, found no significant weight loss over placebo. Anyone describing AOD-9604 as a trial-backed fat-loss peptide is describing trials that reached the opposite conclusion. If weight loss is the goal, the best peptides for weight loss sets out the medications with human evidence for it.

What the research describes. The 2001 International Journal of Obesity paper tested the fragment in cells engineered to carry the human growth hormone receptor. It did not compete with growth hormone for the receptor and did not drive cell proliferation. Across the six human trials, IGF-1, the main growth factor growth hormone raises, did not change on treatment.

Evidence type. Cell, with human support on the specific point of IGF-1.

What it means. This is the best supported statement about AOD-9604, and it is a statement about what it does not do. It is why AOD-9604 is described as leaving the growth hormone axis alone, and why someone who wants to avoid raising growth hormone or IGF-1 might look at it. It is also why it is paired, in blends, with peptides that do act on that axis. The contrast with a peptide that raises growth hormone is set out in AOD-9604 vs tesamorelin.

What the research describes. In the 2000 rat study, euglycaemic clamp testing found no adverse effect on insulin sensitivity, in contrast to what chronic growth hormone does. In the 2001 mouse study, unlike growth hormone, the fragment did not raise blood glucose or reduce insulin secretion. In the human trials, glucose tolerance was not impaired.

Evidence type. Animal, with human support.

What it means. This is often presented online as a metabolic benefit. It is more accurately a safety finding: AOD-9604 did not cause the blood-sugar problems that full-length growth hormone causes. No study has shown that it improves blood sugar or insulin sensitivity in people. The intravenous trials did record unspecified low blood sugar among reported effects, so anyone who takes a glucose-lowering medication should list it on the intake.

What the research describes. The two small intravenous studies reported a rise in circulating free fatty acids within hours of a dose.

Evidence type. Human, short-term.

What it means. It is a blood marker consistent with fat being released from storage, measured in a handful of men given the peptide into a vein. It did not translate into significant weight loss in those studies, and it has never been measured after a subcutaneous injection. It is the reasoning some prescribers give for directing a morning dose before eating; that is a rationale, not a trial result.

What the research describes. A 2015 paper in Annals of Clinical and Laboratory Science injected AOD-9604 into the knees of rabbits with collagenase-induced osteoarthritis, weekly for four to seven weeks, with or without hyaluronic acid. Treated joints scored better on gross and microscopic cartilage assessment than saline-treated joints, and the combination with hyaluronic acid scored better than either alone.

Evidence type. Animal.

Strength. One study, in one animal model, by injection directly into the joint, not under the skin. There is no human study of AOD-9604 for any joint condition and no study of subcutaneous dosing for joints. This is the entire basis of the joint claims attached to the peptide.

What the research describes. Nothing directly. No human study has measured body composition after subcutaneous AOD-9604, and the longest trial of any route ran 24 weeks.

What prescribers report. Where prescribers describe change at all, it is modest and framed as support for a diet and training program that is already working, not as a driver of results on its own. These are patterns described by prescribers, not trial endpoints, and nobody can attach a number or a timeline to them.

Evidence type. None direct.

• Weight loss in humans. The largest trial found none over placebo, and the smaller ones found nothing significant.
• An effect size or a timeline for body composition change by subcutaneous injection, because that has never been studied in people.
• Any effect on joints or cartilage in humans.
• That AOD-9604 improves blood sugar. The trials report it did not worsen glucose tolerance, which is a different statement.
• Long-term safety beyond the 24 weeks of the longest trial.
• Efficacy for any condition as an FDA-approved treatment. It is not approved for anything.

The FDA reached the same reading. In 2023 it placed AOD-9604 in Category 2 of its interim 503A bulk substances list; it left that category on 27 September 2024 when the nominations were withdrawn. On 4 December 2024 the FDA's Pharmacy Compounding Advisory Committee voted 0 to 12 against adding it to the 503A Bulks List, having evaluated it for obesity, and the FDA's briefing document cited a lack of evidence of effectiveness by any route, the failed OPTIONS trial, and the absence of human data for the subcutaneous route. That vote is a recommendation, the FDA has not issued a final rule, and AOD-9604 remains legal for a physician to prescribe and a licensed pharmacy to compound. Some sources claim FDA "GRAS" status for AOD-9604; as of September 2026 there is no GRAS notice for it in the FDA's inventory, and it would have no bearing on a prescription injection in any case.

Adverse events in the trials were similarly distributed between AOD-9604 and placebo, and no serious adverse event was judged related to treatment. AOD-9604 is not used in pregnancy or breastfeeding. It is prohibited at all times under the WADA List as a growth hormone fragment, and anti-doping laboratories have published a urine detection method for it; see peptides for athletes. The full list, with the FDA's caveats, is in AOD-9604 side effects.

Every price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Refills run every 28 days, one vial per fill. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The unit and milligram arithmetic is in AOD-9604 dosage.

AOD-9604 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

Pepti prescribes AOD-9604 in every state except Oklahoma, plus DC The step-by-step page is how to get AOD-9604 prescribed online.